Adalimumab Archives - Medical Conferences

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

Biologics in psoriatic arthritis: where we are and where we are headed

Presented By

Dr Vinod Chandran

Conference

IFPA 2024

Type

News article

17 July 2024 11:55

Biologicals and JAK inhibitors hold promise in microscopic colitis

Presented By

Dr Bram Verstockt, University Hospitals Leuven, Belgium

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:35

How effective is dose escalation of biologicals in IBD?

Presented By

Dr Cristina Rubín de Célix, University Hospital La Princesa, Spain

Trial

RAINBOW-IBD

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:30

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression

Presented By

Prof. Xenofon Baraliakos, Rheumazentrum Ruhrgebiet, Germany

Trial

Phase 3, SURPASS

Conference

EULAR 2023

Type

Peer-reviewed article

31 July 2023 06:22

Anti-TNF withdrawal may be a safe option in stable IBD

Presented By

Prof. María Chaparro Sánchez , Hospital Universitario de La Princesa, Spain

Trial

Phase 4, EXIT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:12

Intensified drug therapy leads to better stricture morphology in CD

Presented By

Dr Julien Schulberg , St Vincent’s Hospital Melbourne, Australia

Trial

STRIDENT

Conference

ECCO 2023

Type

Peer-reviewed article

4 May 2023 16:03

Dose-interval of adalimumab might be prolonged in CD patients in stable remission

Presented By

Dr Reinier van Linschoten , Franciscus Gasthuis en Vlietland, the Netherlands

Trial

Phase 4, LADI

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 17:01

High rate of non- or partial responders jeopardises therapeutic success in HS

Presented By

Dr Hayley Wallinger, Adelphi Real World, UK

Conference

EADV 2022

Type

Peer-reviewed article

5 November 2022 11:15

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

How to treat enthesitis in 2022

Presented By

Prof. Dennis McGonagle, University of Leeds, United Kingdom

Trial

Phase 3, SEAM-PsA, EXCEED, SPIRIT-H2H

Conference

EULAR 2022

Type

Peer-reviewed article

21 July 2022 17:42

Dermatology diseases need the highest doses of biologics

Presented By

Dr Charlotte Greif, Beth Israel Deaconess Medical Center, USA

Conference

AAD 2022

Type

Peer-reviewed article

17 May 2022 12:24

Early biologic therapy induces larger effect than delayed treatment in Crohn’s disease

Presented By

Prof. Shomron Ben-Horin, Tel-Aviv University, Israel

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 17:21

Anti-TNFs versus vedolizumab and ustekinumab in Crohn’s disease

Presented By

Dr Neeraj Narula, McMaster University, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:46

Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis

Presented By

Prof. Remo Panaccione , University of Calgary, Canada

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:44

Tapering biologics: No alarming signs of increased anti-drug antibodies

Presented By

Dr Juul van den Reek , Radboudumc, the Netherlands

Trial

Phase 4, CONDOR

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:43

HLA-C*06:02-positive patients on ustekinumab show higher drug survival in a real-world scenario

Presented By

Dr Oras Alabas, University of Manchester, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 14:05

Protective factors identified against anti-drug antibody formation to adalimumab in psoriasis

Presented By

Dr Teresa Tsakok, King’s College London, UK

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:37

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

Potential role of inflammation in cardiovascular comorbidity

Presented By

Dr Alexander Egeberg, Herlev and Gentofte Hospital, Denmark

Trial

Phase 3, CANTOS, CIRT

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:13

ECCO 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECCO 2021

10 August 2021 08:17

ABBV-3373: A potential new therapeutic agent for RA

Presented By

Dr Frank Buttgereit, Charité University Medicine, Germany

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 19:05

Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD

Presented By

Dr Peter Irving, Guy’s and St. Thomas’ Hospital, UK

Trial

SEAVUE

Conference

ECCO 2021

Type

News article

2 July 2021 23:45

Risk of hospitalisation and surgery linked to IBD biological

Presented By

Dr Camilla Bjørn Jensen, Frederiksberg Hospital

Conference

ECCO 2021

Type

News article

2 July 2021 20:20

Obesity increases the risk of immunogenicity to adalimumab in IBD

Presented By

Dr Remi Mahmoud, University Medical Centre Utrecht, the Netherlands

Conference

ECCO 2021

Type

News article

2 July 2021 14:24

No elevated risk for influenza AE in tofacitinib-treated RA patients

Conference

ACR 2020

Type

Peer-reviewed article

18 January 2021 10:42

Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio

Presented By

Dr Laura Coates, Oxford University, United Kingdom

Trial

Phase 4, CONTROL

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:09

Upadacitinib provides fast onset of improvement in psoriatic arthritis

Presented By

Prof. Iain McInnes, University of Glasgow, Scotland

Trial

SELECT-PsA-1

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 14:02

Secukinumab monotherapy as efficient as adalimumab

Presented By

Prof. Iain McInnes, University of Glasgow, United Kingdom

Trial

Phase 3, EXCEED

Conference

EULAR 2020

Type

Peer-reviewed article

14 August 2020 13:11

Biologics in HS – a growing armamentarium

Presented By

Prof. Joslyn Kirby, Penn State University, USA

Trial

PIONEER

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 12:48

Biologic psoriasis treatment to lower cardiovascular risk?

Presented By

Prof. Joel Gelfand, University of Pennsylvania, USA

Conference

AAD 2020

Type

Peer-reviewed article

6 August 2020 08:01

Effects of vedolizumab versus adalimumab on QoL

Presented By

Dr E.V. Loftus, Mayo Clinic, USA

Trial

VARSITY

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:39

Vedolizumab and anti-TNF therapies: a real-world comparison

Presented By

Dr G. Mantzaris , Evangelismos Hospital, Greece

Trial

EVOLVE

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:35

Vedolizumab, adalimumab, and golimumab compared

Presented By

Dr F.S. Macaluso & Dr A. Casanotti

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 15:32

High versus standard adalimumab in active UC

Presented By

Prof. J. Colombel, Icahn School of Medicine at Mount Sinai, USA

Trial

Phase 3, SERENE-UC

Conference

ECCO 2020

Type

Peer-reviewed article

14 April 2020 14:47

TNFi for RA during pregnancy – to stop or not to stop?

Presented By

Dr Isabell Haase, Heinrich-Heine University Düsseldorf, Germany

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 10:16

Biologics: increasingly used in paediatric dermatology

Presented By

Prof. Marieke Seyger, Radboud University Nijmegen, the Netherlands

Conference

EADV 2019

Type

Peer-reviewed article

9 December 2019 15:16

ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker

Presented By

Prof. Diamant Thaçi, University of Lübeck, Germany

Trial

ESPRIT

Conference

EADV 2019

Type

Peer-reviewed article

9 October 2019 19:23

Switching upadacitinib and adalimumab is beneficial in refractory RA

Trial

Phase 3, SELECT-COMPARE

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 17:54

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 11:20

Switch to sarilumab from adalimumab is efficacious and safe

Presented By

Dr Gerd Burmester, Free University and Humboldt University of Berlin, Germany

Trial

MONARCH

Conference

EULAR 2019

Type

Peer-reviewed article

4 September 2019 10:07

Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity

Presented By

Dr Gayle van der Kraaij, Amsterdam UMC, the Netherlands

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 20:57

ABP501 biosimilar for adalimumab: What you need to know

Presented By

Prof. Brian Kirby, St Vincent's Hospital, Dublin, Ireland

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 17:24

Vedolizumab superior to adalimumab in ulcerative colitis

Presented By

Dr Stefan Schreiber, University-Hospital Schleswig-Holstein, Germany

Trial

Phase 3, VARSITY

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 22:57

Proactive adalimumab trough measurements

Presented By

Dr Amit Assa, Schneider Children’s Hospital, Israel

Conference

ECCO 2019

Type

Peer-reviewed article

9 May 2019 10:20

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:06

Biologic drug levels and infection risk, and clinical effectiveness of sarilumab

Trial

TARGET

Conference

EULAR 2018

Type

Peer-reviewed article

24 August 2018 19:30

Confirmation of long-term safety profile adalimumab across indications

Presented By

Prof. Gerd Burmester, Charité University Hospital, Free University and Humboldt University of Berlin, Germany

Conference

EULAR 2018

Type

Peer-reviewed article

24 August 2018 18:39

Combining new drugs with different mechanisms

Trial

EXPLORER

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 23:31

Long-term safety profile of adalimumab

Trial

ULTRA 1, ULTRA 2

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 22:07

Targeting early disease: lessons from rheumatoid arthritis

Trial

OPTIMA

Conference

ECCO 2018

Type

Peer-reviewed article

28 May 2018 19:27